Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceTWST +4.43%69 Cash Ratio is 1.39 as of Jun. 2026, which is 73% below its 10-year median of 5.11. GuruFocus rates TWST with a GF Score™ of 69/100 and a GF Value™ of $52.17 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Twist Bioscience ranks better than 60.39% on this metric.
Twist Bioscience (NAS:TWST) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Twist Bioscience Cash Ratio Related Terms
Twist Bioscience Cash Ratio Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Twist Bioscience's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (TWST) has a Cash Ratio of 1.39 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Twist Bioscience and its competitors. This is 73% below median its historical median of 5.11. Over the past decade, Twist Bioscience's Cash Ratio has ranged from 1.39 to 15.83. According to the industry distribution chart, Twist Bioscience ranks #82 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 39.6%.
Is Twist Bioscience's Cash Ratio too high?
Twist Bioscience's current Cash Ratio of 1.39 is 73% below median its 10-year median of 5.11. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 15.83. The Medical Diagnostics & Research industry median Cash Ratio is 0.99. Twist Bioscience's value of 1.39 is 40.4% above this industry median. Based on the distribution chart, Twist Bioscience ranks #82 out of 207 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Cash Ratio compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #82 out of 207 companies for Cash Ratio. This puts Twist Bioscience in the upper half of its industry. The industry median Cash Ratio is 0.99. Twist Bioscience's value of 1.39 is 40.4% above this benchmark. Historically, Twist Bioscience's own Cash Ratio has ranged from 1.39 to 15.83 over the past decade. While the company's 10-year median is 5.11 vs. the industry median of 0.99, Twist Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.99, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Twist Bioscience's current Cash Ratio of 1.39 is 40.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Twist Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current Cash Ratio is 1.39, which is 73% below median its own 10-year median of 5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.17, compared to a current price of $113.91 — trading 118.3% above its estimated fair value. The current Cash Ratio is 1.39, which is 73% below median its 10-year median of 5.11 and 40.4% above the Medical Diagnostics & Research industry median of 0.99. Twist Bioscience's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Twist Bioscience (TWST), the current Cash Ratio is 1.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $113.91 is trading 118.3% above its estimated GF Value™ of $52.17.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
Cash Ratio: 1.39 (73% below median its 10-year median of 5.11)
GF Value™: $52.17 vs. price of $113.91 (118.3% above fair value)
Industry Position: 40.4% above the Medical Diagnostics & Research median (#82 of 207)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
